Ovarian

Arrow In this section

Introduction

Patients with platinum sensitive relapsed ovarian cancer and germline or somatic mutations in BRCA1/2 may benefit from treatment with the poly ADP ribose polymerase (PARP) inhibitor Lynparza (Olaparib). BRCA1/2 mutation screening in blood or FFPE tissue can identify patients with BRCA1/2 mutations who may benefit from targeted therapy.

Please refer to the National Genomic Test Directory for Cancer here.

Reporting times

  • Ovarian panel (FFPE) 21 calendar days
  • Ovarian panel (Germline) 42 calendar days

Requesting a test

Please refer to our Sample Requirements section before sending any samples to us for testing.

Please use this form to request this test from us.